Jul 17,2017

Abbott, Bigfoot Biomedical collaborate on diabetes technologies

Abbott and Bigfoot Biomedical have entered into an agreement to develop and commercialize diabetes management systems, integrating Abbott's FreeStyle Libre glucose sensing technology with Bigfoot's insulin delivery solutions. Under the agreement, Abbott will supply glucose measurement sensors for all of Bigfoot's insulin delivery systems in the U.S. as the exclusive sensors for those systems. Bigfoot, meanwhile, will develop and commercialize multiple systems using Abbott's FreeStyle Libre sensor technology -- including systems designed to perform auto-titration for Bigfoot's connected insulin injection devices -- as well as automated insulin delivery using Bigfoot's insulin infusion platform.

COLLABORATION PARTNERSHIP

#connected device

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Jul 25,2017

Roche joins Senseonics, TypeZero for artificial pancreas trials

Senseonics and TypeZero's R&D partnership around the artificial pancreas is leveling up. The two organizations announced today that they would team up with pharmaceutical and medical device company Roche to launch three European clinical trials of their combined closed-loop system. The research is backed by the National Institutes of Health (NIH) through its International Diabetes Closed Loop (IDCL) Trial program. In this new partnership, Senseonics and TypeZero are working with Roche on a system that will combine Eversense, TypeZero’s inControl AP algorithms and Roche’s Accu-Chek Insight Insulin Pump.

COLLABORATION PARTNERSHIP

#r&d

#closed loop

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jul 03,2017

South Manchester GPs offer ground-breaking diabetes support

Changing Health, the service transforming digital education and support for people with diabetes, is now available for thousands of people with diabetes in South Manchester to rapidly improve their health outcomes. A new partnership between Changing Health and South Manchester GP Federation means an estimated 12,000 people with Type 2 diabetes – 7.6% of the population covered by the Federation’s 24 member practices – can now access the service.

COLLABORATION PARTNERSHIP

#product & service

#coaching

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 10,2017

DarioHealth Receives “First Choice” Recognition in the UK

DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that the CCGs (Clinical Commissioning Groups) in three UK regions have named the Dario™ Blood Glucose Monitoring System the first choice for all patients with type 1 diabetes, in the area of “Smart meters with Carb counting.”

PRODUCT

#bgm

View Analyst & Ambassador Comments
Go to original news
Jul 10,2017

Nemaura Medical Inc. announces uplist to OTCQB

Nemaura Medical Inc. (OTC: NMRD), a medical technology company focused on the development and commercialization of sugarBEAT®, a wireless disposable adhesive skin-patch for adjunctive use by diabetics as a non-invasive and needle-free continuous glucose monitoring (CGM) system announced it has recently uplisted to the OTCQB Venture Market trading platform.

View Analyst & Ambassador Comments
Go to original news
Jul 11,2017

Fit4D (now named Cecelia Health) Receives Highest Rating for Social Impact From GIIRS, Global Impact Investing Rating System

Fit4D (now named Cecelia Health), a leading diabetes patient engagement solution, has earned a Platinum overall Impact Business Model rating (the highest rating available) by GIIRS, the Global Impact Investing Rating System. GIIRS was developed by B Lab, a non-profit dedicated to supporting for-profit companies to use the power of business to solve social and environmental problems.

View Analyst & Ambassador Comments
Go to original news
Jul 13,2017

Tandem Diabetes Care Schedules Second Quarter 2017 Earnings Press Release and Conference Call

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, plans to release its second quarter 2017 results after the financial markets close on Thursday, July 27, 2017. The Company will hold a conference call and simultaneous webcast on the same day at 4:30pm Eastern Time (1:30pm Pacific Time), to discuss its second quarter 2017 financial and operating results.

View Analyst & Ambassador Comments
Go to original news
Jul 13,2017

Insulet Corporation to Announce Second Quarter 2017 Financial Results on August 3, 2017

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the second quarter of 2017 on August 3, 2017 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

View Analyst & Ambassador Comments
Go to original news
Jul 17,2017

Nemaura Appoints Timothy Johnson to Board of Directors as Independent Director, Chairman of Audit and Corporate Governance Committees

Nemaura Medical Inc. (OTCQB: NMRD), a medical technology company focused on the development and commercialization of sugarBEAT®, a wireless disposable adhesive skin-patch for adjunctive use by diabetics as a non-invasive and needle-free continuous glucose monitoring (CGM) system announced today that it has appointed Timothy Johnson to the company’s Board of Directors. Mr. Johnson will serve as an independent director of the company and chair the board’s Audit and Nominating and Corporate Governance Committees.

View Analyst & Ambassador Comments
Go to original news
Jul 20,2017

DarioHealth Receives U.S. FDA Clearance for Certain Leading Android Devices in the U.S.

DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that the United States Food and Drug Administration (FDA) has granted Pre-market Notification (510(k)) clearance for the Dario app on certain leading Android smart mobile devices (SMD).

REGULATORY FDA

#mobile app

#bgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES